SCHEMBL14865200

SCHEMBL14865200

C=C/C=C(\C=C/C)C(N)=O

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
FGFR4 P22455 1/20 0.32
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27575135 1.00 ALDH1A1 (0.32) ALDH1A1TSHRFGFR4TDP1
SCHEMBL8344137 0.82
SCHEMBL27574963 0.82
SCHEMBL14922420 0.81
SCHEMBL25038788 0.80
SCHEMBL14240725 0.80
SCHEMBL21307660 0.80
SCHEMBL13618856 0.79 ALDH1A1 (0.33) ALDH1A1TSHRFGFR4
SCHEMBL12698403 0.79
SCHEMBL24932910 0.79 ALDH1A1 (0.33) ALDH1A1TSHRFGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017161119-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-09-21 WO disclosed
EP-2922841-B1 ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2017-06-07 EP disclosed
US-9637518-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-02 US disclosed
US-20160367535-A1 Methods and Compositions for Controlling Ectoparasites HATCHTECH PTY LIMITED (AU) 2016-12-22 US disclosed
US-9028873-B2 Nanoparticles for drug delivery to the central nervous system SOUTHWEST RESEARCH INSTITUTE (US) 2015-05-12 US disclosed
EP-2398780-B1 CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR ASTRAZENECA AB (SE) 2013-04-17 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG ALDH1A1 600/4885TSHR 449/4885FGFR4 194/4885
US-20160367535-A1 Methods and Compositions for Controlling Ectoparasites CAT, CMA1, CTRL ALDH1A1 2615/4885TSHR 2161/4885FGFR4 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.